These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21210260)

  • 1. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.
    Valenzuela B; Nalda-Molina R; Bretcha-Boix P; Escudero-Ortíz V; Duart MJ; Carbonell V; Sureda M; Rebollo JP; Farré J; Brugarolas A; Pérez-Ruixo JJ
    AAPS J; 2011 Mar; 13(1):72-82. PubMed ID: 21210260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.
    Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2013 Dec; 52(12):1111-25. PubMed ID: 23828617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
    Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin.
    Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
    AAPS J; 2016 Jan; 18(1):239-50. PubMed ID: 26577587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients.
    Pérez-Ruixo C; Peris JE; Escudero-Ortiz V; Bretcha-Boix P; Farré-Alegre J; Pérez-Ruixo JJ; Valenzuela B
    Cancer Chemother Pharmacol; 2014 May; 73(5):1009-20. PubMed ID: 24663502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.
    Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of heated intraperitoneal oxaliplatin.
    Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
    Elias D; Bonnay M; Puizillou JM; Antoun S; Demirdjian S; El OA; Pignon JP; Drouard-Troalen L; Ouellet JF; Ducreux M
    Ann Oncol; 2002 Feb; 13(2):267-72. PubMed ID: 11886004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
    Elias D; Matsuhisa T; Sideris L; Liberale G; Drouard-Troalen L; Raynard B; Pocard M; Puizillou JM; Billard V; Bourget P; Ducreux M
    Ann Oncol; 2004 Oct; 15(10):1558-65. PubMed ID: 15367418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of oxaliplatin after intraperitoneal administration with hyperthermia in Wistar rats.
    Mas-Fuster MI; Ramon-Lopez A; Lacueva FJ; Arroyo A; Más-Serrano P; Nalda-Molina R
    Eur J Pharm Sci; 2018 Jul; 119():22-30. PubMed ID: 29626594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
    Elias D; El Otmany A; Bonnay M; Paci A; Ducreux M; Antoun S; Lasser P; Laurent S; Bourget P
    Oncology; 2002; 63(4):346-52. PubMed ID: 12417789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats.
    Mas-Fuster MI; Ramon-Lopez A; Lacueva J; Compañ A; Más-Serrano P; Nalda-Molina R
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):621-627. PubMed ID: 28168311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.
    Cashin PH; Ehrsson H; Wallin I; Nygren P; Mahteme H
    Eur J Clin Pharmacol; 2013 Mar; 69(3):533-40. PubMed ID: 22983312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers.
    Stewart JH; Shen P; Russell G; Fenstermaker J; McWilliams L; Coldrun FM; Levine KE; Jones BT; Levine EA
    Ann Surg Oncol; 2008 Aug; 15(8):2137-45. PubMed ID: 18493824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model.
    Piché N; Leblond FA; Sidéris L; Pichette V; Drolet P; Fortier LP; Mitchell A; Dubé P
    Ann Surg; 2011 Jul; 254(1):138-44. PubMed ID: 21494122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid correction of severe hyperglycaemia during hyperthermic intraperitoneal chemoperfusion with oxaliplatin.
    Cammu G; De Gendt S; Vandeput D; Foubert L
    Acta Chir Belg; 2009; 109(2):256-9. PubMed ID: 19499696
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers.
    Dumont F; Passot C; Raoul JL; Kepenekian V; Lelièvre B; Boisdron-Celle M; Hiret S; Senellart H; Pein F; Blanc-Lapierre A; Raimbourg J; Thibaudeau E; Glehen O;
    Eur J Cancer; 2020 Nov; 140():37-44. PubMed ID: 33039812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.
    Srinivas NR
    Eur J Clin Pharmacol; 2009 Mar; 65(3):321-2. PubMed ID: 19011850
    [No Abstract]   [Full Text] [Related]  

  • 20. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
    Elias D; Pocard M; Goere D
    Cancer Treat Res; 2007; 134():303-18. PubMed ID: 17633062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.